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Purpose: The efficacy of accelerated partial breast irradiation (APBI) utilizing brachyther-
apy or conventional external beam radiation has been studied in early-stage breast 
cancer treated with breast-conserving surgery. Data regarding stereotactic treatment 
approaches are emerging. The CyberKnife linear accelerator enables excellent dose 
conformality to target structures while adjusting for target and patient motion. We report 
our institutional experience on the technical feasibility and rationale for stereotactic 
accelerated partial breast irradiation (SAPBI) delivery using the CyberKnife radiosurgery 
system.
Methods: Ten patients completed CyberKnife SAPBI (CK-SAPBI) in 2013 at Georgetown 
University Hospital. Four gold fiducials were implanted around the lumpectomy cavity 
prior to treatment under ultrasound guidance. The synchrony system tracked intrafraction 
motion of the fiducials. The clinical target volume was defined on contrast enhanced CT 
scans using surgical clips and post-operative changes. A 5 mm expansion was added to 
create the planning treatment volume (PTV). A total dose of 30 Gy was delivered to the 
PTV in five consecutive fractions. Target and critical structure doses were assessed as 
per the National Surgical Adjuvant Breast and Bowel Project B-39 study.
results: At least three fiducials were tracked in 100% of cases. The Mean treated PTV 
was 70 cm3 and the mean prescription isodose line was 80%. Mean dose to target 
volumes and constraints are as follows: 100% of the PTV received the prescription dose 
(PTV30). The volume of the ipsilateral breast receiving 30 Gy (V30) and above 15 Gy 
(V > 15) was 14 and 31%, respectively. The ipsilateral lung volume receiving 9 Gy (V9) 
was 3%, and the contralateral lung volume receiving 1.5 Gy (V1.5) was 8%. For left-
sided breast cancers, the volume of heart receiving 1.5 Gy (V1.5) was 31%. Maximum 
skin dose was 36 Gy. At a median follow-up of 1.3 years, all patients have experienced 
excellent/good breast cosmesis outcomes, and no breast events have been recorded.
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conclusion: CyberKnife stereotactic accelerated partial breast irradiation is an 
 appealing technique for partial breast irradiation offering improvements over existing 
APBI techniques. Our early findings indicate that CK-SAPBI delivered in five daily frac-
tions is feasible, well tolerated, and is a reliable platform for delivering APBI.
Keywords: breast cancer, breast sBrT, cyberKnife breast, partial breast irradiation, aPBi, stereotactic 
radiosurgery, breast radiosurgery
inTrODUcTiOn
Breast-conserving therapy (BCT) is the preferred treatment 
approach for early-stage breast cancer and numerous randomized 
controlled studies have demonstrated equivalent overall survival 
for patients receiving breast-conserving surgery with whole breast 
irradiation (WBI) compared with patients treated by mastectomy 
alone (1–4). These studies demonstrate ~70% reduction in local 
recurrence with the addition of adjuvant radiation after breast-
conserving surgery (5) and a reduction in the risk of breast cancer 
death by one-sixth at 15 years (6). Despite the known advantages 
of BCT, its utilization remains low with only 10–80% of eligible 
patients completing treatment. Prolonged treatment time, cost, 
distance to treatment facilities, and patient inconvenience have 
been implicated as possible deterrents to BCT (7–10).
Accelerated partial breast irradiation (APBI) delivers a high 
dose of radiation therapy to the region around the lumpectomy 
cavity (11, 12). However, current APBI techniques have significant 
drawbacks. For instance, balloon-based brachytherapy applicators 
may not be suitable for cavities close to the skin surface or for 
irregularly shaped cavities to which the balloon cannot conform 
(13). Air and fluid pockets in the lumpectomy cavity can create 
dosimetric aberrations requiring adjustments (14). External beam 
APBI (EB-APBI) is subject to intra-fractional motion, surface 
deformation, and treatment set-up uncertainties that have to be 
accounted for with increases in the planning target volume (PTV) 
resulting in larger amounts of normal breast tissue receive high-
dose irradiation and increased risk of poor cosmesis (15–17).
CyberKnife stereotactic accelerated partial breast irradiation 
(CK-SAPBI) offers technical improvements in partial breast 
irradiation using real-time tracking, respiratory motion manage-
ment, and submillimeter accuracy with few technical limitations 
(18, 19). Reduced target and treatment uncertainty allows for 
treatment intensification, maximal target coverage reminiscent 
of high-dose brachytherapy while protecting normal breast tis-
sue from unnecessary high-dose irradiation (20–22). With these 
technical improvements, we expect more women will be eligible 
for CK-SAPBI with similar local control, increased patient con-
venience, and improved cosmesis compared to existing EB-APBI 
techniques. We present our early institutional experience with the 
technical set-up, treatment planning, and dosimetric parameters 
of 10 patients receiving CK-SAPBI.
MaTerials anD MeThODs
Patient selection
This restrospective analysis was approved by the hospital institu-
tional review board. Most patients were “suitable” or “cautionary” 
according to ASTRO consensus guidelines for APBI (23). Patients 
were aged ≥48 years with stage 0 or I histologically confirmed 
invasive non-lobular carcinoma or ductal carcinoma in  situ 
(DCIS). Tumor size was required to be ≤2  cm in maximum 
diameter and surgically excised with negative margins ≥2 mm. 
Patients with invasive ductal carcinoma underwent negative 
sentinel sampling.
Prior to CK-SAPBI treatment, all patients were evaluated by 
a single board certified radiation oncologist and were seeking 
adjuvant treatment with PBI only. Patients with large seromas 
or hyper deformable breast tissue (poor breast integrity) were 
not offered CK-SAPBI. These patients were deemed to be poor 
candidates for fiducial tracking purposes based on previous 
unpublished institutional experience. All patients opted for 
CK-SAPBI after discussing risks and alternatives, including 
standard WBI. Written informed consent was obtained outlining 
the above discussion.
Treatment Planning and immobilization
Prior to treatment, four 2-mm gold fiducials (Best Medical 
International Inc.) were implanted around the lumpectomy site 
under ultrasound guidance by a single board certified radiologist. 
Pre-surgical imaging was used to guide optimal fiducial place-
ment. For optimal tracking, fiducials must be non-coplanar 
and have an angular separation of at least 15° between any two 
fiducials. Thus, fiducials were placed at the 12:00, 6:00, 10:00, 
and 4:00  rad relative to the lumpectomy cavity to satisfy these 
constraints. Contrast-enhanced 1-mm CT scans were obtained 
in the supine position with patient arms placed by their sides 
approximately 1  week after fiducials were placed. No breast 
immobilization devices were required.
The CT images were exported to the MultiPlan treatment plan-
ning software (Accuray Incorporated, Sunnyvale, CA, USA). The 
lumpectomy cavity and post-surgical changes were identified and 
a target region was manually defined around them with additional 
soft tissue margins confined to the breast tissue and skin contour 
to generate a clinical target volume (CTV). Pre-operative imaging 
was used to assist target definition when artifacts or tissue density 
interfered with delineation. A uniform 5-mm expansion was used 
to generate the PTV. The arms were contoured and no beam entry 
or exit was permitted through the arms. The ipsilateral breast, 
contralateral breast, skin, chest wall, lungs, heart, and thyroid 
were delineated and designated avoidance structures.
Inverse CyberKnife plans were generated to deliver 30 Gy in five 
fractions to the PTV over consecutive days. This corresponds to a 
biologically effective dose equivalent to 50 Gy in 25 fractions assum-
ing an α/β for tumor control of 4 Gy (24). Formenti initially published 
their experience using this fractionation scheme with excellent local 
TaBle 1 | Patients and tumor characteristics.
Value
Age (years)
Mean (range) 61 (48–77)
Tumor histology
IDC 3
DCIS 7
Stage
Tis 7
T1b 2
T1c 1
Tumor size (centimeter)
Mean (range) 0.95 (0.3–2.0)
IDC 1.2 (1.0–1.5)
DCIS 0.8 (0.3–2.0)
Laterality
Right 6
Left 4
Quadrant
Central 1
UOQ 5
UIQ 3
LIQ 1
Nodal stage
NX 7
N0 3
ASTRO APBI Consensus Group Suitable-3 Cautionary-6 Unsuitable-1
Other
ER positive 9
Cup size B-2, C-4, D-1, DD-1
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; UOQ, upper outer 
quadrant; UIQ, upper inner quadrant, LIQ, lower inner quadrant; NX, lymph nodes not 
sampled; N0, sampled lymph nodes were negative; ER, estrogen receptor.
3
Obayomi-Davies et al. CyberKnife Accelerated Partial Breast Irradiation
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 129
control rates and good cosmesis at a median follow-up of 5 years (25). 
This dose scheme was also employed in the randomized controlled 
phase III trial of WBI versus PBI using IMRT (26).
All patient plans were generated using the MultiPlan treatment 
planning system (version 4.6.0). Dose distribution calculations 
were performed using Monte Carlo dose calculation algorithm 
with heterogeneity correction. Dose volume histogram (DVH) 
assessments were performed to determine if institutional dose 
constraints were met. For the purpose of this study, DVH analyses 
were performed and compared to external beam PBI constraints 
in the National Surgical Adjuvant Breast and Bowel Project B-39/
Radiation Therapy Oncology group 0413 (NSABP/RTOG) study.
Follow-up
Follow-up visits were conducted by the treating physician 4 weeks 
after the completion of treatment and at scheduled intervals 
thereafter per routine practice. Breast examinations and sched-
uled mammograms were performed to assess local control and 
changes in the appearance of the breast. Toxicity and cosmesis 
were assessed by a single physician using the Harvard scale of 
cosmetic outcome.
resUlTs
Between 2/2013 and 12/2013, 10 patients received CK-SAPBI. 
Table 1 provides a summary of patient demographics and tumor 
characteristics. All four fiducials were successfully tracked during 
treatment in 60% of cases. At least three fiducials were success-
fully tracked during treatment in all patients. The mean number 
of beams delivered was 155 (119–194). Figures 1 and 2 illustrate 
a typical treatment plan and DVH. The mean treated PTV vol-
ume was 70 cm3 (range = 35–142 cm3) with a mean prescription 
isodose line of 80% (range = 77–87%).
Dose volume histogram analysis of organs at risk is summa-
rized in Table 2. In four patients, the tumor beds were located 
in the inner quadrant increasing the contralateral breast dose. 
In each case, less than 10% of the contralateral breast volume 
received above 2 Gy for the entire treatment. One patient had an 
ipsilateral lung V9Gy above 15%. This patient had a deep-seated 
tumor close to the chest wall and was an outlier in our series.
Minimal toxicity was observed following treatment. One 
patient has not returned for follow-up. Among returning patients, 
with a maximum follow-up of 1.6 years (range = 0.1–1.5 years, 
median 1.25 years), no adverse breast events have been recorded. 
One patient had grade 1 skin induration 3  weeks after treat-
ment which resolved without intervention. No other skin, lung, 
chest wall, or breast toxicity has been observed. All patients 
experienced excellent/good cosmetic outcomes following treat-
ment. Figure 3 illustrates a patient with a left-sided upper inner 
quadrant CK-SAPBI treatment with excellent cosmetic outcome 
15 months following treatment.
DiscUssiOn
Partial breast irradiation is a promising treatment technique for 
the treatment of early-stage breast cancer. Multiple randomized 
trials are evaluating treatment outcomes but early available data 
are encouraging and suggest low recurrence rates in well-selected 
women. CK-SAPBI is a convenient alternative with meaningful 
technical improvements compared to existing partial breast 
irradiation techniques.
The CyberKnife radiosurgery system has been used suc-
cessfully at our institution since early 2002. We sought to apply 
our vast experience in treating cranial, spine, lung, prostate, 
and pancreatic tumors to adjuvant APBI. We carefully selected 
patients with favorable pathologic features to minimize the risk 
of ipsilateral breast recurrence. Furthermore, we avoided patients 
with large seromas and poor breast integrity to avoid sub-optimal 
fiducial tracking. Our CK-SAPBI experience thus far is encourag-
ing and confirms our presumptions about the feasibility of the 
CyberKnife radiosurgery system in delivering targeted APBI. 
The minimal treatment volumes and high dose conformity are 
reminiscent of high dose rate interstitial brachytherapy without 
its known technical challenges and invasive requirements making 
CK-SAPBI quite appealing.
CyberKnife stereotactic accelerated partial breast irradia-
tion offers additional advantages of fewer treatments delivered 
and increased patient comfort due to lack of a second surgical 
procedure to place the brachytherapy applicator. Furthermore, 
concerns regarding worse cosmetic outcomes with APBI are 
FigUre 2 | cumulative dose volume histogram (DVh) for the target PTV and normal tissues. This plan was normalized to deliver 30 Gy to the PTV. 
Unlabeled structures: left lung; purple. Right lung; yellow. Right breast; light blue.
FigUre 1 | axial, sagittal, and coronal views of the treatment planning cT scan demonstrating the PTV (purple) and normal breast (pink), isodose 
lines shown as follows: 100% of the prescription dose, red line; 50% of the prescription dose, green line; arrow points to gold fiducial marker.
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likely abated with CK-SAPBI. Prior to publication of the RAPID 
trial interim analysis showing unacceptable worse cosmesis in the 
3D-CRT arm, lager treatment volumes had been associated with 
worse breast cosmesis after EB-PBI (27). With a mean treated 
PTV of 70cm3 in our series, we expect favorable long-term cos-
mesis and at median follow-up of 1.25 years cosmetic outcomes 
remain excellent/good.
While the technical advantages over existing PBI platforms 
are evident, potential disadvantages exist with CK-SAPBI. 
First, since fiducials are required to track target motion, proper 
fiducial positioning is crucial. Fiducial migration can occur after 
placement, hindering optimal real-time tracking. As such, our 
practice is to obtain our treatment planning imaging at least 
7 days following fiducial implantation to allow for tissue recovery. 
FigUre 3 | Frontal view of bilateral breasts showing excellent breast 
cosmesis 18 months following cyberKnife saPBi. SAPBI, Stereotactic 
accelerated partial breast irradiation.
TaBle 2 | Dose limitations for normal tissue based on the nsaBP/rTOg 
B-39 protocol for patients treated with cyberKnife saPBi to a total dose 
of 30 gy delivered in five fractions (n = 10).
structure constraint cyberKnife Treatment  
(mean, range)
Ipsilateral breast V30 < 35% 14%, 3–26%
V15 < 60% 31%, 8–58%
Contralateral breast Dmax < 1 Gy 3 Gy, 0–11 Gy
Ipsilateral lung V9 < 15% 3%, 0–17%
Contralateral lung V1.5 < 15% 8%, 0–21%
Heart (left breast) V1.5 < 40% 31%, 7–43%
Heart (right breast) V1.5 < 5% 18%, 0–37%
Thyroid Dmax < 1 Gy <1 Gy, 0–1.4 Gy
Skin Dmax < 36 Gy 32 Gy, 28–36 Gy
Chest wall Dmax < 36 Gy 26 Gy, 13–33 Gy
SAPBI, stereotactic accelerated partial breast irradiation; NSABP, National Surgical 
Adjuvant Breast and Bowel Project; RTOG, Radiation Therapy Oncology Group; 
3D-CRT, three-dimensional conformal radiotherapy.
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Moreover, fiducial tracking can be sub-optimal in patients with 
poor breast integrity and large post-operative seromas. Second, 
CK-SAPBI treatment times are prolonged compared to 3D-CRT 
and IMRT treatments. However, this trade-off is likely acceptable 
given the reduced treatment volume and higher treatment con-
formity afforded by CyberKnife treatment delivery. Finally, delin-
eation of the lumpectomy cavity can be difficult. This  difficulty 
is particularly pronounced with oncoplastic reconstructions and 
when clips have not been placed to delineate the surgical cavity. 
A commercially available three-dimensional (3D) bioabsorbable 
tissue marker (BioZorb, Focal Therapeutics, Portola Valley, CA, 
USA) offers profound improvements in this regard. The rigid lat-
tice of the BioZorb preserves the 3D location of the lumpectomy 
cavity even after oncoplastic reconstruction (28).
Our study is limited by its small size, short follow-up, and 
retrospective nature. The results are nonetheless encouraging and 
we have concluded that CK-SAPBI is a reasonable non-invasive 
APBI delivery platform in early-stage breast cancer. Additional 
patients will be evaluated to determine the optimal patient 
population for this treatment approach. To this effect, we have 
commissioned a prospective phase II trial to further evaluate 
CK-SAPBI in early-stage breast cancer.
cOnclUsiOn
Stereotactic accelerated partial breast irradiation via CyberKnife 
is a suitable platform for partial breast irradiation offering 
improvements over existing APBI techniques. Our experience 
confirms previous reports regarding CK-SAPBI and suggests that 
this technique is feasible for the delivery of APBI.
aUThOr’s nOTe
Meeting Presentation: Preliminary results of this study were 
presented at the 97th annual American Radium Society meeting 
in 2015 in Kauai, HI from May 2nd to 5th, 2015.
aUThOr cOnTriBUTiOns
OO-D, BC, TK, LC, BO, SW, ET, EM, and SR all contributed to 
study concept, design, and/or acquisition of data. OO-D, TK, 
HA, KU, and BC completed the data collection. BC and OO-D 
contributed to the data analysis. OO-D was responsible for 
drafting the manuscript. All authors contributed to revising and 
giving final approval to the manuscript. All authors agree to be 
accountable for all aspects of the work including its accuracy 
and integrity.
acKnOWleDgMenTs
Rashid Abdul provided physics and data extraction support for 
the production of the manuscript. Anatoly Dritschilo provided 
guidance and critical review during project development.
reFerences
1. NIH consensus conference. Treatment of early-stage breast cancer. JAMA 
(1991) 265:391–5. doi:10.1001/jama.1991.03460030097037
2. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. 
Twenty-year follow-up of a randomized trial comparing total mastectomy, 
lumpectomy, and lumpectomy plus irradiation for the treatment of invasive 
breast cancer. N Engl J Med (2002) 347:1233–41. doi:10.1056/NEJMoa022152 
3. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. 
Long-term results of a randomized trial comparing breast-conserving therapy 
with mastectomy: European Organization for Research and Treatment of Cancer 
10801 trial. J Natl Cancer Inst (2000) 92:1143–50. doi:10.1093/jnci/92.14.1143 
4. Blichert-Toft M, Rose C, Andersen JA, Overgaard M, Axelsson CK, 
Andersen KW, et al. Danish randomized trial comparing breast conser-
vation therapy with mastectomy: six years of life-table analysis. Danish 
Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr (1992) 
(11):19–25. 
5. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et  al. 
Twenty-year follow-up of a randomized study comparing breast-conserving 
surgery with radical mastectomy for early breast cancer. N Engl J Med (2002) 
347:1227–32. doi:10.1056/NEJMoa020989 
6. EBCTCG. Effects of radiotherapy and surgery in early breast cancer. An 
overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative 
Group. N Engl J Med (1995) 333:1444–55.
6Obayomi-Davies et al. CyberKnife Accelerated Partial Breast Irradiation
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 129
7. Morrow M, White J, Moughan J, Owen J, Pajack T, Sylvester J, et al. Factors 
predicting the use of breast-conserving therapy in stage I and II breast carci-
noma. J Clin Oncol (2001) 19(8):2254–62. 
8. Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic 
variation in the use of breast-conserving treatment for breast cancer. N Engl 
J Med (1992) 326:1102–7. doi:10.1056/NEJM199204233261702 
9. Legorreta AP, Liu X, Parker RG. Examining the use of breast-conserving 
treatment for women with breast cancer in a managed care environment. Am 
J Clin Oncol (2000) 23:438–41. doi:10.1097/00000421-200010000-00002 
10. Arthur DW, Vicini FA. Accelerated partial breast irradiation as a part of 
breast conservation therapy. J Clin Oncol (2005) 23:1726–35. doi:10.1200/
JCO.2005.09.045 
11. Swanson TA, Vicini FA. Overview of accelerated partial breast irradiation. 
Curr Oncol Rep (2008) 10:54–60. doi:10.1007/s11912-008-0009-8 
12. Belkacemi Y, Chauvet MP, Giard S, Villette S, Lacornerie T, Bonodeau F, et al. 
Partial breast irradiation as sole therapy for low risk breast carcinoma: early tox-
icity, cosmesis and quality of life results of a MammoSite brachytherapy phase 
II study. Radiother Oncol (2009) 90:23–9. doi:10.1016/j.radonc.2008.06.004 
13. Vicini FA, Keisch M, Shah C, Goyal S, Khan AJ, Beitsch PD, et  al. Factors 
associated with optimal long-term cosmetic results in patients treated with 
accelerated partial breast irradiation using balloon-based brachytherapy. Int 
J Radiat Oncol Biol Phys (2012) 83:512–8. doi:10.1016/j.ijrobp.2011.07.011 
14. Huang YJ, Blough M. Dosimetric effects of air pocket sizes in MammoSite 
treatment as accelerated partial breast irradiation for early breast cancer. 
J Appl Clin Med Phys (2009) 11(1):2932. 
15. Yue NJ, Goyal S, Kim LH, Khan A, Haffty BG. Patterns of intrafractional 
motion and uncertainties of treatment setup reference systems in accelerated 
partial breast irradiation for right- and left-sided breast cancer. Pract Radiat 
Oncol (2014) 4:6–12. doi:10.1016/j.prro.2012.12.003 
16. Yue NJ, Goyal S, Zhou J, Khan AJ, Haffty BG. Intrafractional target motions 
and uncertainties of treatment setup reference systems in accelerated 
partial breast irradiation. Int J Radiat Oncol Biol Phys (2011) 79:1549–56. 
doi:10.1016/j.ijrobp.2010.05.034 
17. Jagsi R, Ben David MA, Moran JM, Marsh RB, Griffith KA, Hayman JA, et al. 
Unacceptable cosmesis in a protocol investigating intensity-modulated radio-
therapy with active breathing control for accelerated partial-breast irradiation. 
Int J Radiat Oncol Biol Phys (2010) 76:71–8. doi:10.1016/j.ijrobp.2009.01.041 
18. Vermeulen S, Cotrutz C, Morris A, Meier R, Buchanan C, Dawson P, et al. 
Accelerated partial breast irradiation: using the CyberKnife as the radiation 
delivery platform in the treatment of early breast cancer. Front Oncol (2011) 
1:43. doi:10.3389/fonc.2011.00043 
19. Vermeulen SS, Haas JA. CyberKnife stereotactic body radiotherapy and 
CyberKnife accelerated partial breast irradiation for the treatment of 
early breast cancer. Transl Cancer Res (2014) 3(4):295–302. doi:10.3978/j.
issn.2218-676X.2014.07.06
20. Xu Q, Chen Y, Grimm J, Fan J, An L, Xue J, et al. Dosimetric investigation 
of accelerated partial breast irradiation (APBI) using CyberKnife. Med Phys 
(2012) 39:6621–8. doi:10.1118/1.4757616 
21. Heinzerling JH, Ding C, Ramirez E, Chang K, Anderson JF, Edwards CM, et al. 
Comparative dose-volume analysis for CyberKnife and 3D conformal partial 
breast irradiation treatment of early stage breast cancer. Int J Radiat Oncol Biol 
Phys (2010) 78:S825–6. doi:10.1016/j.ijrobp.2010.07.1911 
22. Fan J, Hayes S, Freedman G, Anderson P, Li J, Wang L, et al. Planning the 
breast boost: dosimetric comparison of CyberKnife, photon mini tangents, 
IMRT, and electron techniques. Int J Radiat Oncol Biol Phys (2014) 78:S788–9. 
doi:10.1016/j.ijrobp.2010.07.1826 
23. Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh 
PH, et al. Accelerated partial breast irradiation consensus statement from the 
American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol 
Phys (2009) 74:987–1001. doi:10.1016/j.ijrobp.2009.02.031 
24. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et  al. 
Effect of radiotherapy fraction size on tumour control in patients with 
early-stage breast cancer after local tumour excision: long-term results of a 
randomised trial. Lancet Oncol (2006) 7:467–71. doi:10.1016/S1470-2045(06) 
70699-4 
25. Formenti SC. External-beam partial-breast irradiation. Semin Radiat Oncol 
(2005) 15:92–9. doi:10.1016/j.semradonc.2004.10.008 
26. Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et  al. 
Accelerated partial breast irradiation using intensity-modulated radiotherapy 
versus whole breast irradiation: 5-year survival analysis of a phase 3 ran-
domised controlled trial. Eur J Cancer (2015). doi:10.1016/j.ejca.2014.12.013 
27. Lewin AA, Derhagopian R, Saigal K, Panoff JE, Abitbol A, Wieczorek 
DJ, et  al. Accelerated partial breast irradiation is safe and effective using 
intensity-modulated radiation therapy in selected early-stage breast cancer. 
Int J Radiat Oncol Biol Phys (2012) 82:2104–10. doi:10.1016/j.ijrobp.2011. 
02.024 
28. Smith LA, Kuske RR, Cross MJ. Improved targeting of the lumpectomy cavity 
using a spiral 3-D marker. Int J Radiat Oncol (2014) 90:S276. doi:10.1016/j.
ijrobp.2014.05.944
Conflict of Interest Statement: BC, SC, and OO-D are paid speakers for Accuray. 
The remaining authors have no competing interests.
Copyright © 2016 Obayomi-Davies, Kole, Oppong, Rudra, Makariou, Campbell, 
Anjum, Collins, Unger, Willey, Tousimis and Collins. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
